NEW YORK (GenomeWeb News) – Proteomics International recently announced an agreement with inVentiv Health Clinical aimed at the development of biosimilars.

As part of the deal, Perth, Australia-based Proteomics International's services aimed at structural characterization and quality control testing of proposed and referenced products will be combined with inVentiv's bioanalytical capabilities.

The New Jersey-based firm provides drug development services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.